HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Chongqing Zhifei Biological Products / Equity Bottom-Up

Chongqing Zhifei Biological Products (300122 CH)

<ul>
<li>Due to the lack of competitiveness, Zhifei’s self-developed products cannot contribute solid performance to make up for the shrinking revenue of HPV vaccines when more competing products gradually launched.</li>
<li>The real potential of HPV vaccine market in China is not as big as imagined. So, the companies involved have the problem of inflated market values.</li>
<li>Due to low demand of COVID-19 vaccine/negative impact of pandemic on HPV vaccination, Zhifei's revenue YoY growth could be 10%-20%; Net profit YoY growth could be negative in 2022.</li>
</ul>


Due to the lack of competitiveness, Zhifei’s self-developed products cannot contribute solid performance to make up for the shrinking revenue of HPV vaccines when more competing products gradually launched.
The real potential of HPV vaccine market in China is not as big as imagined. So, the companies involved have the problem of inflated market values.
Due to low demand of COVID-19 vaccine/negative impact of pandemic on HPV vaccination, Zhifei's revenue YoY growth could be 10%-20%; Net profit YoY growth could be negative in 2022.


Zhifei Biological Products (300122.CH) - More Downside Ahead, with Untenable Logic in HPV Vaccine

External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Jiangsu Recbio Technology / Equity Bottom-Up

<div><div><div><ul><li>Recbio reported RMB350mn net loss for 1H22, vs RMB330mn net loss in 1H21.</li><li>R&amp;D expense increased by 73% YoY to RMB354mn in 1H22, mainly due to clinical trial expenses related to the Ph III trial of REC603 and PhII/III trials of ReCOV.</li><li>On 25 Aug, Recbio received a formal acceptance letter from China Securities Regulatory Commission, for the implementation of its H Share full circulation plan to convert 222.5mn Domestic Shares into H Shares.</li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Recbio reported RMB350mn net loss for 1H22, vs RMB330mn net loss in 1H21.R&amp;D expense increased by 73% YoY to RMB354mn in 1H22, mainly due to clinical trial expenses related to the Ph III trial of REC603 and PhII/III trials of ReCOV.On 25 Aug, Recbio received a formal acceptance letter from China Securities Regulatory Commission, for the implementation of its H Share full circulation plan to convert 222.5mn Domestic Shares into H Shares.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Recbio Technology (2179 HK) – Smooth progress of core pipeline products

<ul>
<li>Under the current policy in China, any minor changes to vaccine doses require a series of clinical data support and registration changes. So, WHO’s recommendation won’t affect Zhifei’s short-term performance.</li>
<li>The increasing domestic competing HPV vaccines in the future would be a big threat to Zhifei’s agency business. Its self-developed products may not be strong enough to compensate. </li>
<li>The performance in 2022 is expected to be solid before real challenge comes in 2024. The valuation logic and outlook won’t be brighten unless there’s new breakthrough in agency business.</li>
</ul>


Under the current policy in China, any minor changes to vaccine doses require a series of clinical data support and registration changes. So, WHO’s recommendation won’t affect Zhifei’s short-term performance.
The increasing domestic competing HPV vaccines in the future would be a big threat to Zhifei’s agency business. Its self-developed products may not be strong enough to compensate. 
The performance in 2022 is expected to be solid before real challenge comes in 2024. The valuation logic and outlook won’t be brighten unless there’s new breakthrough in agency business.


Chongqing Zhifei Biological Products (300122.CH) - WHO's One-Dose HPV Vaccine Regimen & The Outlook

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/v3-brands-asia" target="_blank" data-smartkarma-citation="entities:35797:1" rel="noopener">V3 Brands Asia (V3 HK)</a> is looking to raise about US$500m in its upcoming Hong Kong IPO. It was previously listed on the SGX between 2000-2016.</li>
<li>V3 Brands Asia is a lifestyle and wellness firm, it is most known for its flagship massage chairs which are sold under the OSIM brand.</li>
<li>In this note, we'll talk about the not so positive aspects of the deal.</li>
</ul>



V3 Brands Asia (V3 HK) is looking to raise about US$500m in its upcoming Hong Kong IPO. It was previously listed on the SGX between 2000-2016.
V3 Brands Asia is a lifestyle and wellness firm, it is most known for its flagship massage chairs which are sold under the OSIM brand.
In this note, we'll talk about the not so positive aspects of the deal.


V3 Brands Asia Pre-IPO - The Negatives - While Margins Have Grown, so Have Payouts to Founder

<ul>
<li>
<a href="https://www.smartkarma.com/entities/v3-brands-asia" target="_blank" data-smartkarma-citation="entities:35797:1" rel="noopener">V3 Brands Asia (V3 HK)</a> is looking to raise about US$500m in its upcoming Hong Kong IPO. It was previously listed on the SGX between 2000-2016.</li>
<li>V3 Brands Asia is a lifestyle and wellness firm, it is most known for its flagship massage chairs which are sold under the OSIM brand.</li>
<li>It has also recorded a bounce back post-COVID as average revenue per store surged. Margins have expanded as well owing to operating leverage and the firm’s partnership with Daito-OSIM.</li>
</ul>



V3 Brands Asia (V3 HK) is looking to raise about US$500m in its upcoming Hong Kong IPO. It was previously listed on the SGX between 2000-2016.
V3 Brands Asia is a lifestyle and wellness firm, it is most known for its flagship massage chairs which are sold under the OSIM brand.
It has also recorded a bounce back post-COVID as average revenue per store surged. Margins have expanded as well owing to operating leverage and the firm’s partnership with Daito-OSIM.


V3 Brands Asia Pre-IPO - The Positives - Margins and Revenue Have Grown

China

Jiangsu Recbio Technology is an innovative vaccine company dedicated to the research, development, production, and commercialization of recombinant protein vaccines and related adjuvant technologies. Its pipeline includes vaccines for cervical cancer, shingles, COVID-19, influenza, and tuberculosis. The company was founded in 2012 and is headquartered in Taizhou, Jiangsu, PRC.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Recbio Technology (2179 HK)

Zhifei Biological Products (300122.CH) - More Downside Ahead, with Untenable Logic in HPV Vaccine

Zhifei’s HPV vaccine will face real risk as competing products launch from 2024. The real potential of China HPV vaccine market is much lower than...

Xinyao (Criss) Wang

Recbio Technology (2179 HK) – Smooth progress of core pipeline products

R&D expense increased by 73% YoY to RMB354mn in 1H22, mainly due to clinical trial expenses related to the Ph III trial of REC603 and PhII/III...

CMB International

Chongqing Zhifei Biological Products (300122.CH) - WHO's One-Dose HPV Vaccine Regimen & The Outlook

WHO’s recommendation on HPV vaccines is not the biggest risk of Zhifei and won't affect short-term performance, but the valuation logic...

Xinyao (Criss) Wang

V3 Brands Asia Pre-IPO - The Negatives - While Margins Have Grown, so Have Payouts to Founder

V3 Brands Asia (V3 HK) is looking to raise about US$500m in its upcoming Hong Kong IPO. In this note, we'll talk about the not so positive aspects...

Clarence Chu

V3 Brands Asia Pre-IPO - The Positives - Margins and Revenue Have Grown

V3 Brands Asia (V3 HK) is looking to raise about US$500m in its upcoming Hong Kong IPO. It was previously listed on the SGX between 2000-2016.

Clarence Chu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)